Last Posted: Feb 15, 2017
New blood biopsies with experimental device may improve cancer diagnosis and follow-up
Science Magazine, February 13, 2017
Grail to pour $1 billion into blood test to detect early cancer
C Sheridan, Nat Biotechnology, February 7, 2017
Circulating Tumor DNA May Serve as a Prognostic Marker in Pancreatic Cancer
J Cavallo, ASCO Post, December 20, 2016
Circulating tumor DNA technology: the future of cancer management?
L Blackburn, PHG Foundation, December 20, 2016
Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study
CA Parkinson et al, PLOS Medicine, December 20, 2016
KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients.
Garzón Mónica et al. Translational lung cancer research 2016 Oct 5(5) 511-516
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.